Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Retained Earnings: 2017-2024

Historic Retained Earnings for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to -$902.9 million.

  • Aclaris Therapeutics' Retained Earnings fell 17.57% to -$948.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$948.0 million, marking a year-over-year decrease of 17.57%. This contributed to the annual value of -$902.9 million for FY2024, which is 17.13% down from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Retained Earnings is -$902.9 million, which was down 17.13% from -$770.8 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Retained Earnings registered a high of -$504.5 million during FY2020, and its lowest value of -$902.9 million during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$770.8 million (2023), whereas its average is -$785.3 million.
  • Data for Aclaris Therapeutics' Retained Earnings shows a maximum YoY dropped of 18.01% (in 2021) over the last 5 years.
  • Aclaris Therapeutics' Retained Earnings (Yearly) stood at -$504.5 million in 2020, then dropped by 18.01% to -$595.4 million in 2021, then declined by 14.60% to -$682.3 million in 2022, then declined by 12.97% to -$770.8 million in 2023, then fell by 17.13% to -$902.9 million in 2024.